IP Library Granted Patent US 7,772,379
Granted Patent B2
US 7,772,379 · App. 11/777,057 · Granted Aug 10, 2010

Compositions and processes for preparing 13-deoxy-anthracyclines

Assignee: Gem Pharmaceuticals, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,772,379
App. No.
11/777,057
Granted
Aug 10, 2010
Kind
B2
Abstract

13-benzenesulfonylhydrazone anthracyclines useful in producing improved yields in the synthesis 13-deoxyanthrcyclines, and an improved method of reducing 13-benzene-sulfonylhydrazone anthracyclines to 13-deoxyanthrcyclines wherein the reduction reaction is maintained at temperatures of about 55° C. to 64° C. without stirring or agitation. The reaction is completed with the addition of aqueous bicarbonate which forms the 13-deoxyanthracycline and precipitates. The precipitates are filtered and the precipitate and filtrate are extracted separately with organic solvents. The crude 13-deoxy anthracycline can be converted to 5-imino-13-deoxy anthracycline by reaction with methanolic ammonia. The reaction can also be performed with an acidic pyridinium salt instead of a strong acid so that neutralization of the reaction or extraction of the product is not necessary, thereby facilitating purification.

Claims (25)

1. A compound represented by the formula:

wherein:

R 1 , R 2 and R 3 are H or OH;

R 4 is H, OH, alkyl, or O-alkyl;

R 5 is O or NH; and

R 6 is a sugar moiety

wherein the sugar moiety is

2. The compound of claim 1 , wherein the compound is a derivative of an anthracycline selected from the group consisting of epirubicin, and annamycin.

3. A method for producing a compound according to claim 1 which comprises reacting a 13-keto anthracycline or acid salt thereof with benzene-sulfonylhydrazide in an alcohol solvent at about 35 to 50° C. for about 10 to 24 hours.

4. A process for preparing 13-deoxy anthracyclines, comprising:

1) forming an alcohol solution of a 13-benzene-, or substituted benzene-, sulfonylhydrazone anthracycline;

2) adding a reducing agent and an acidic pyridinium salt to the solution; and

3) heating the solution to reduce the 13-benzene-, or substituted benzene-, sulfonylhydrazone anthracycline,

wherein the acidic pyridinium salt is pyridinium p-toluenesulfonate and the reducing agent is sodium cyanoborohydride.

5. The process according to claim 4 , further comprising the step of hydrolyzing the reduced 13-benzene-sulfonylhydrazone anthracycline, thereby forming the 13-deoxy anthracycline.

6. The process according to claim 4 wherein the heating is at about 65° C. to about 75° C.

7. The process according to claim 4 wherein the 13-benzene-sulfonylhydrazone anthracycline is a derivative of an anthracycline selected from the group consisting of epirubicin, and annamycin.

8. A process for preparing a 5-imino-13-deoxy anthracyclines, comprising:

1) preparing a 13-deoxy anthracycline according to claim 4 ; and

2) converting the 13-deoxy anthracycline to the corresponding 5-imino-13-deoxy anthracycline with ammonia at less than about 20° C.,

wherein the 13-deoxy anthracycline is synthesized from a corresponding 13-benzenesulfonylhydrazone anthracycline.

9. The process according to claim 8 wherein the step of converting the 13-deoxy anthracycline to the corresponding 5-imino-13-deoxy anthracycline with ammonia is at about 1° C. to about 4° C. for 1 to 4 days.

10. The process according to claim 8 wherein the 13-deoxy anthracycline is selected from the group consisting of the 13-deoxy forms of epirubicin, and annamycin.

11. The compound of claim 1 , wherein R 6 is

12. The compound of claim 1 , wherein R 6 is

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Sep 28, 2017
From: PHARMA INVESTMENTS LLC
To: GEM PHARMACEUTICALS, LLC
Reel/Frame 044049/0716 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2017
From: GEM PHARMACEUTICALS, LLC
To: TACTICGEM, LLC
Reel/Frame 044100/0957 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2017
From: TACTICGEM, LLC
To: MONOPAR THERAPEUTICS INC.
Reel/Frame 044100/0977 →
SECURITY AGREEMENT Recorded Jan 25, 2010
From: GEM PHARMACEUTICALS, LLC
To: PHARMA INVESTMENTS LLC
Reel/Frame 023839/0564 →
Continuity (2)
Continuation 1098287300 · Nov 8, 2004
Related Publication 20080015345A1 · Jan 17, 2008